uniQure N.V. (QURE)

By Nathan Miller

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE). Investors who purchased uniQure securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether uniQure has violated federal securities laws.

uniQure Investigation Details

On September 29, 2026, uniQure released 48-month clinical data for AMT-130, its investigational gene therapy for Huntington’s disease. Although the Company reported continued evidence of slowed disease progression, the four-year results did not meet a key statistical measure and appeared less favorable than the earlier three-year data that had been used to support a Biologics License Application. The results raised investor concerns regarding the therapy’s long-term durability and prospects for regulatory approval. Following this news, uniQure’s stock price opened down nearly 40% on September 29, 2026.

What’s Next for uniQure Investors?

If you are aware of any facts relating to this investigation or purchased uniQure securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to uniQure Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC For uniQure Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]

Attorney advertising.
Prior results do not guarantee similar outcomes.